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The immune responses of mice immunized with ovalbumin (OVA) together with killed L. major 
(KLM) promastigotes as adjuvant were studied.  Three doses  (5 × 107, 1 × 108 and 2 × 108) of KLM 
combined with OVA (100 µg) were injected into the groups of C57BL/6 mice.  BCG and complete 
Freund’s adjuvant (CFA) were used as control adjuvants. Lymphocyte proliferation and antibody 
titers were determined, and IFN-γ and IL-4 were measured in the supernatants of lymph node cell 
cultures. Results showed that immunization using OVA mixed with KLM enhanced the in vitro 
proliferative response of T-cells to the antigen and resulted in the production of increased levels of 
IFN-γ (2800-3700 pg/ml) relative to the mice injected with OVA alone (1750 pg/ml). In the mice 
receiving OVA + 5 × 107 KLM, the production of IL-4 remained lower (18, 20 pg/ml) than OVA alone 
(105, 109 pg/ml) and almost was similar to that of observed in mice inoculated with OVA + BCG, 
leading to high IFN-γ/IL-4 ratios. Using higher doses of KLM (1 × 108), the IL-4 responses were of the 
same magnitude as or higher than the responses of mice inoculated with OVA + CFA.  Antibody titers 
to OVA were also strongly boosted at the highest KLM dose. These findings indicate that KLM may 
function as an adjuvant, and its dose plays a role in the eventual outcome of the response. Inoculation 
of the mice with a low dose of KLM (5 × 107) tends to promote a Th1-type response.  Iran. Biomed. J. 6 
(4): 123-128, 2002 
 





eishmania parasites are protozoan micro-
organisms that infect the cells of the 
mononuclear phagocyte series in their 
vertebrate host. The infection elicits a strong 
humoral or cell-mediated immune response, or both, 
depending on the infecting species and on 
characteristics of the host. A number of similarities 
can be noted between the immune responses elicited 
by these organisms and Mycobacteria: a) Protective 
immunity induced by both organisms is T-cell 
mediated and macrophage plays a crucial role as 
immune effector cell [1-3]; b) Leprosy and 
leishmaniasis are characterized by well-defined 
polar forms in both infections. The localized 
tuberculoid form is accompanied by strong lympho-
cyte proliferation and the IFN-γ production in 
response to antigen challenge in vitro [4]; c) 
Polarization of the immune responses towards 
protection (induced by the Th1 subset) or to 
exacerbation (induced by the Th2 subset) has been 
documented in both L. major and M. leprae 
infections [5]; d) In experimental murine 
leishmaniasis, innate immunity is controlled by Lsh 
gene that is thought to be identical to the Bcg gene 
[6]; e) T cell clones from individuals vaccinated 
against BCG or killed Leishmania show significant 
INF-γ production.  Both types of clones are of CD4+ 
phenotype, and the antigen recognized by these 
clones may be involved in protection against re-
infection [7, 8]; f) the existence of antigenic cross-
reactivity between both organisms has been well 
documented [9, 10].  
The use of BCG as an adjuvant has been well 
established for many years [11]. Immunotherapy of 
the patients with leishmaniasis using killed parasites 
plus live BCG has been carried out successfully 
[12].  Furthermore, in vaccine trials using killed L. 
major candidate vaccine, BCG is commonly used as 
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an adjuvant [13-16]. However, adverse effects or 
complications have been reported in the use of 
BCG, including inflammatory arthritis and 
autoimmune reactions [17-19]. On the other hand, 
inoculation of killed Leishmania is fully innocuous, 
as proved by the use of leishmanin as skin test 
antigen (Montenegro test) for several decades [20].  
Leishmania promastigotes are easily cultured in 
monophasic media. It was therefore of interest to 
examine whether L. major could exert an adjuvant 
effect on the immune response of mice to some 
unrelated antigens. 
In the present work, the potential adjuvant effect 
of KLM promastigotes was tested in mice. 
Ovalbumin (OVA), a T-dependent antigen, also 
used as a carrier in experimental model [21], was 
chosen as an immunogen, and CFA or BCG as 
control adjuvants.  Antibody responses, T-cell 




MATERIALS AND METHODS 
 
Animals and parasites.  Female 
C57BL/6 mice (7-8 week-old) were used 
in these experiments and the original 
stock was purchased from IFFA CREDO 
(St. Gerrmain-sur-l'Arbresle, France). 
The experimental animals were obtained 
from the Animal Breeding Center of the 
Pasteur Institute of Iran.  The strain of L. 
major (MRHO/IR/75/ER), kindly 
provided by Dr. E. Javadian (School of 
Public Health, Tehran University of 
Medical Sciences, Iran) was used in the 
experiment as adjuvant. Parasites were 
grown in Novy-MacNeal-Nicole (NNN) 
medium, and then were transferred to 
RPMI (Sigma, Germany) supplemented 
with 0.2 mM L-glutamine, 100 U/ml 
penicillin, 100 µg streptomycin and 15% 
fetal bovine serum (FBS).  The 
stationary phase promastigotes were 
harvested, washed, killed by 0.05 % 
thimerosal, disrupted by 7 cycles of 
freezing and thawing and then kept at -
70°C until use. 
 
Immunization protocol.  Seven groups 
of 10 mice each were injected with OVA 
alone (100 µg/100 µl), OVA + 5 × 107 
KLM, OVA + 1 × 108 KLM, OVA + 2 × 
108 KLM, OVA + BCG (Pasteur 
Institute of Iran, 6-7 × 107 CFU/ml), and 
OVA + CFA (Sigma, 50 µl), 
respectively, and a control group injected 
only with PBS. Each mouse in group 2-6 
received OVA in 100 µg/50 µl + 
adjuvant in 50 µl volume. A total volume 
of approximately 100 µl was injected 
subcutaneously at the base of the tail.  
The amount of OVA used for each 
mouse was 100 µg and the same amount 
was injected to 5 mice as a booster 
without adjuvant one week later.    
 
Lymphocyte proliferation assay.  
Inguinal and periaortic lymph nodes 
(LN) of mice were removed 20 days 
after the second immunization. Pooled 
LN cells from 5 mice were cultured as 
described [22]. Briefly, the viability of 
the cells was evaluated with trypan blue 
exclusion, and viable lymphocytes (4 × 
105) were cultured for 4 days in 200 µl 
enriched RPMI 1640 medium 
(supplemented with 2 mM L-glutamine 
(Sigma), and 10% FBS, 10 mM HEPES, 
5 × 10-5 M 2-ME, 100 U/ml penicillin, 
and 100 µg/ml streptomycin) in the 
presence of 250 µg/ml of OVA, a 
concentration found in pilot experiments 
to provide an optimal response. Con A 
was used as a positive, and medium 
alone as a negative control. The 
proliferative response to antigen was 
quantified by measurement of 3H-
methyl-thymidine uptake (Amersham, 
UK). This test was repeated three times. 
 
Cytokine production and assessment. 
Mono-nuclear lymph node cells (2 × 106) 
were cultured as above in 1.0 ml 
complete medium in the presence of 250 
µg/ml OVA in flat-bottomed 24-well 
micro-plates for four days.  Supernatants 
were harvested and stored at -70°C, and 
the concentrations of IFN-γ and IL-4 
were quantified by a sandwich ELISA 
technique using commercial kits 
(Genzyme, USA) according to the 
procedure of the manufacturer. Samples 
were tested in duplicates. Data were 
calculated from reference curves 
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obtained using standards provided in the 
kits. 
 
Antibody measurement.  ELISA was 
used for antibody measurement as 
described [23]. Briefly, 96-well 
microplates were coated with ovalbumin 
(150 µg/well) in carbonate buffer (pH 
9.6) and incubated overnight at 4°C.  
Serum  samples were diluted in 
duplicates in total volume of 200 µl PBS 
at 37°C for 1 h, followed by a peroxidase 
conjugated anti-mouse IgG and IgM 
(Sigma), and substrate (o-
Phenylenediamine in 10 ml citrate buffer 
(pH 5.0), plus 0.02% H2O2. The plates 
were read at 490 nm. 
RESULTS 
 
Induction of a proliferative response.   
Pre-liminary experiments indicated that 
the injection of OVA plus a low dose of 
KLM (4 × 107) capable of increasing the 
proliferative response in LN cells culture 
against OVA antigen when compared to 
mice injected with OVA alone (data not 
shown). In further experiments, mice 
were immunized with OVA + higher 
doses of killed parasites (5 × 107, 1 × 108 
or 2 × 108), which resulted in a much 
higher proliferative responses of LN 
cells to ovalbumin. The results obtained 
using a dose of 108 promastigotes were 
comparable to those achieved in mice 
injected with OVA + BCG, especially 
after the first immunization. As shown in 
Figure 1, KLM increased the 
proliferative response to ovalbumin 
about 12-folds (first immunization), and 
about 3-folds (second immunization), 
relative to OVA alone. Using student’s t-
test a significant difference was observed 
in first (p<0.001) and second (p = 0.001) 
immunization. Similar results were 
obtained in comparison of mice injected 
with OVA + BCG and mice injected 
with OVA alone (p<0.001 for both first 
and second immunization). Interestingly, 
after the first immunization, the 
proliferative response of LN cells of 
mice inoculated with OVA + CFA was 
significantly (p = 0.002) lower than that 
of cells from mice receiving OVA + 
KLM. 
 
Cytokine production.  Immunization of mice with 
OVA + KLM enhanced IFN-δ production in OVA-
stimulated LN cell cultures relative to the lymph 
node cells from the mice injected with OVA alone. 
As shown in Table 1, the effect of KLM was similar 
to that of BCG after both the primary and the 
secondary immunization. However, in mice 
immunized with OVA + CFA, production of IFN-γ 
remained low after the first immunization and 
























Fig. 1. Proliferative responses of lymph node cells from the 
mice immunized with ovalbumin (OVA): adjuvant effect of 
KLM.  Mice (10 per group) were immunized at the base of the 
tail with OVA + 108 killed L. major (KLM), OVA alone, OVA 
+ BCG or OVA + CFA. Five mice from each group were 
boosted after one week by inoculation of OVA alone. Twenty 
days later, periaortic and inguinal lymph nodes were harvested 
and lymphocytes were cultured for 4 days in the absence or 
presence of OVA (250 µg/ml). Proliferation was assessed by 
measurements of 3H-TdR uptakes during the last 18 h of 
culture.  Each column represents the arithmetic mean of 
triplicate determinations and vertical bars show the limits of 
one standard deviation. The results shown are representative of 
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 Table 1. Balance between Th1 and Th2 cytokine production in lymph node cell cultures derived from mice immunized with 
ovalbumin and different adjuvants.  
Cytokine Concentration (pg/ml) Adjuvant No. of  injections 
IFN-γ IL-4 
IFN-γ/IL-4 
1 1,750 105 17 No adjuvant 2 1,750 109 16 
1 3,000 20 150 KLM 5 × 107 2 3,000 18 167 
1 3,700 120 31 KLM 108 2 2,820 131 22 
1 2,800 70 40 KLM 2 × 108 2 2,900 52 56 
1 3,100 35 89 BCG 2 3,000 62 48 
1 780 73 11 CFA 2 2,750 118 23 
Mice received one or two injections of 100 µg of OVA.  Adjuvant was added to the first inoculum.  The inguinal and periaortic 
lymph node cells from 5 mice per group were pooled and re-stimulated in vitro with OVA (250 µg/ml) for 4 days, prior to 
assessment of cytokine concentrations in the culture supernatants. 
Alimohammadian et al. 
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The production of IL-4 in OVA-
stimulated LN cells of the mice 
immunized with OVA plus the smaller 
dose of KLM (5 × 107) was markedly 
lower when compared to the mice 
immunized with OVA alone, after both 
the primary and the secondary 
immunizations. These responses were 
similar to those of control mice receiving 
OVA + BCG, particularly after the first 
immunization. Likewise, the ratio of 
IFN-γ/IL-4 was distinctly higher in the 
group of mice injected with OVA plus 
the lower dose of KLM (5 × 107), 
relative to all the other groups. In 
contrast, higher and somewhat variable 
IL-4 levels were observed in cultures of 
OVA-stimulated LN cells of the mice 
immunized with OVA plus higher doses 
of KLM, correlating with the results of 
the mice injected with OVA + CFA 
(Table 1).  
 
Antibody responses. No obvious effect 
of KLM on the primary antibody 
response to OVA could be observed. 
However, high titers of anti-OVA IgG 
antibody were obtained in mice 
immunized with OVA + 2 × 108 KLM, 
then boosted with OVA alone, as shown 
in Figure 2.  Lower doses of KLM (5 × 
107) were ineffective as adjuvant for 
antibody production. Higher antibody 
levels still were observed in the mice 
injected with OVA + CFA, whereas 
mice receiving BCG as adjuvant 





The use of BCG as an adjuvant is regarded as an 
acceptable practice in man, and at present this 
adjuvant is routinely used in vaccination and 
immunotherapy trials against leishmaniasis [12-16].  
However, there is evidence that BCG inoculation 
may lead to the development of inflammatory 
arthritis, and it has been suggested that BCG 
immunotherapy may be a trigger mechanism for 
induction of autoimmune reactions [19].  In 
addition, the application of a live vaccine as 
adjuvant may cause complication [18], especially in 
immunocompromised individuals.  Therefore, 
evaluation of the adjuvant effect of KLM may be of 
interest in view of establishing new strategies for 
vaccination or immunotherapy in leishmaniasis and 
other infections. 
The results of the present study indicate that KLM 
does exert an adjuvant effect on the immune 
response to an unrelated soluble antigen, as 
measured by stimulation of the proliferative 























Fig. 2.  Adjuvant effect of KLM on the anti-OVA IgG 
response. Groups of 10 mice were immunized at the base of the 
tail with OVA + different doses of KLM. Five mice from each 
group were boosted after one week with OVA alone.  Twenty 
days later, sera were harvested and tested individually for the 
presence of anti-OVA IgG antibodies by ELISA. The values 
reported in the graph represent the mean of the absorbance 
values found for individual mice within one group; bars 




the production of IFN-γ and serum antibodies. In 
several of these assays, the response obtained using 
KLM was comparable to that of achieved with more 
conventional adjuvants such as BCG or CFA. 
Interestingly, low levels of IL-4 were obtained in 
lymph node cell cultures from the mice injected 
with OVA + the lowest dose of parasites (5 × 107).  
The level of IL-4 in this group of mice was lower 
than that of seen in BCG injected mice, leading to 
the highest IFN-γ/IL-4 ratio observed in this 
experiment. These results are consistent with the 
idea that a low dose of KLM may promote a Th1 
response. However, higher KLM dosages boosted 
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the IL-4 response to levels comparable or higher 
than those seen with BCG or CFA.  
Antibody measurements showed that the mice 
injected with OVA + 1 × 108 KLM developed titers 
similar to those of seen in the mice injected with 
OVA + BCG. Likewise, a marked increase in titer 
was demonstrated in the mice injected with OVA + 
2 × 108 KLM, which was close to that of observed 
in the mice injected with OVA + CFA.  
The combination of KLM with BCG has been 
used in humans by several investigators, in assays 
aimed to assess both its protective effects as a 
vaccine [13-16] and its immunotherapeutical 
potential in Leishmania infections. The later 
strategy was originally devised by Convit et al. 
[12], reported that a percentage of leishmaniasis 
cases with abnormal immunological features 
responded well to this treatment. This approach was 
postulated to exercise its beneficial effect at least 
partly because BCG might promote better antigen 
presentation and stimulate a cellular immune 
response, via secretion of IL-2 and IFN-γ, leading to 
macrophage activation and intracellular parasite 
killing [12]. As shown in this report, Leishmania 
itself appears to be endowed with similar 
characteristics. In the murine model of L. major 
infection, it is now well established that protection 
depends on a cell-mediated immune response with 
expansion of a Th1 subset of lymphocytes [24, 25]. 
Similarly, in some human studies, it was shown that 
T-cell responses and production of IFN-γ in the 
early phase of infection were essential for the 
development of protective immune responses [26, 
27].  Likewise, in vaccine trials in man, conversion 
of Montenegro test as well as IFN-γ production and 
absence of IL-4 secretion have been reported after 
injection of killed leishmanial antigen alone [13, 28, 
29].  Based on the results of this investigation, the 
use of KLM promastigotes as an adjuvant should be 
considered in immunological studies, particularly in 
situations where the selective development of a Th1 
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